Highvista Strategies Portfolio Shifts: Q2 2026 Focus on Biotech Gains
Highvista Strategies' portfolio analysis for Q2 2026 reveals significant new positions and substantial increases in existing holdings, primarily within the biotech sector.
As of June 30th, 2026, Highvista Strategies LLC has maintained a total portfolio value of $392.04 million.
The investment firm's activity report for this quarter highlights several key changes in its holdings:
New Positions and Increased Investments
Highvista Strategies established new positions during Q2 2026, allocating capital to companies like C4 Therapeutics Inc., listed as C4 THERAPEUTICS INC (CCCC). This addition comes with a significant portfolio weighting of approximately 1.44% and shows strong buying momentum, increasing by 100% from the previous period.
Alongside this new entry, Highvista also initiated positions in Relmada Therapeutics Inc., identified as RELMADA THERAPEUTICS INC (RLMD), adding it to its portfolio allocation of 0.7%.
Furthermore, the firm increased its stake in Alkermes PLC, represented by G01767105. The position grew substantially during Q2 with a 144.92% increase in shares, boosting its portfolio percentage to 2.14%. This significant growth also reflects the company's value increasing from $939k.
Other notable increases include substantial additions to Tango Therapeutics Inc., which saw a 149.6% share increase, and significant holdings like Relay Therapeutics Inc. (RLAY) with a nearly 20% share rise during the quarter.
The investor also bolstered its position in USA Today Co Inc., listed under GCI, which increased by 100%. Additionally, there were considerable additions to positions like ALUMIS INC (ALMS) and ENLIVEN THERAPEUTICS INC (ELVN), both showing strong investor confidence with percentage increases of 77.07% and 88.59%, respectively.
Minor Adjustments
In contrast to the significant buying activity, Highvista made minor adjustments in some holdings during Q2. This includes a small decrease in Banco Bradesco S A (BBD), which saw its portfolio allocation drop to 0.08% following an approximately 50.48% reduction in shares.
These changes reflect the dynamic nature of Highvista's investment strategy, focusing on capitalizing on growth opportunities while managing existing positions according to their performance and strategic fit.